AmsterdamVyvgart, Argenx’s blockbuster, failed to beat placebo in Sjögren’s.
The setback is unusual for a company that has racked up a series of autoimmune wins.
Vyvgart blocks the FcRn receptor so the body clears IgG antibodies faster, which works in antibody-driven diseases.
Argenx shares fell 13% Thursday morning.
How each outlet framed it
- STAT leans critical
- highlights setback as unusual given Argenx's track record of autoimmune disease wins, notes immediate 13% stock decline
Sources: STAT